Staphylococcal Skin Infections

Top drugs studied for this disease

All Approvals Safety alerts Label changes Trial results Research Guidance Withdrawals

EMA withdrawal · 2019-03-15
EMA Withdrawn: Altargo (retapamulin) — Glaxo Group Ltd
The EMA withdrew Altargo (retapamulin) from the market for impetigo and staphylococcal skin infections.